Kaho Shionoya

Tokyo, 1628640, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Receptor recognition of hepatitis B and D viruses: Structural insight and its application to drug discovery.

Receptor recognition of hepatitis B and D viruses: Structural insight and its application to drug discovery.

Journal: Antiviral research
Published: March 14, 2026

Structural diversity among animal-derived hepatitis B virus receptor homologues and its significance on determining infection host range

Structural diversity among animal-derived hepatitis B virus receptor homologues and its significance on determining infection host range

Journal: Uirusu
Published: September 28, 2025

Structural mapping of NTCP distinguishes its dual functionality as a hepatitis B virus receptor and bile acid transporter.

Structural mapping of NTCP distinguishes its dual functionality as a hepatitis B virus receptor and bile acid transporter.

Journal: PLoS pathogens
Published: September 17, 2025

Multistep receptor binding of the hepatitis B virus preS1 domain.

Multistep receptor binding of the hepatitis B virus preS1 domain.

Journal: Nature communications
Published: June 03, 2025

Hepatitis B and D virus entry.

Hepatitis B and D virus entry.

Journal: Nature reviews. Microbiology
Published: October 17, 2024

Structural basis for hepatitis B virus restriction by a viral receptor homologue.

Structural basis for hepatitis B virus restriction by a viral receptor homologue.

Journal: Nature communications
Published: August 01, 2024

Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents.

Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents.

Journal: Microbiology spectrum
Published: July 06, 2023

Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments.

Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments.

Journal: The Journal of infectious diseases
Published: November 23, 2022

An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity.

An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity.

Journal: PLoS pathogens
Published: July 01, 2022

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.

Journal: Antiviral research
Published: March 08, 2022

Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro.

Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro.

Journal: Frontiers in microbiology
Published: January 09, 2021

Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment.

Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment.

Journal: iScience
Published: June 07, 2020
Showing 1-12 of 13

Last Updated: 09/26/2026